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Abstract
Electrolyte disorders due to tubular disorders are rare, and knowledge about
validated clinical diagnostic tools such as tubular function tests is sparse.
Reference values for tubular function tests are based on studies with small
sample size in young healthy volunteers. Patients with tubular disorders, how-
ever, frequently are older and can have a compromised renal function. We
therefore evaluated four tubular function tests in individuals with different
ages and renal function. We performed furosemide, thiazide, furosemide-flu-
drocortisone, and desmopressin tests in healthy individuals aged 18–50 years,
healthy individuals aged more than 50 years and individuals with compro-
mised renal function. For each tubular function test we included 10 individu-
als per group. The responses in young healthy individuals were in line with
previously reported values in literature. The maximal increase in fractional
chloride excretion after furosemide was below the lower limit of young
healthy individuals in 5/10 older subjects and in 2/10 patients with compro-
mised renal function. The maximal increase in fractional chloride excretion
after thiazide was below the lower limit of young healthy individuals in 6/10
older subjects and in 7/10 patients with compromised renal function. Median
maximal urine osmolality after desmopressin was 1002 mosmol/kg H2O in
young healthy individuals, 820 mosmol/kg H2O in older subjects and
624 mosmol/kg H2O in patients with compromised renal function. Reference
values for tubular function tests obtained in young healthy adults thus cannot
simply be extrapolated to older patients or patients with compromised kidney
function. Larger validation studies are needed to define true reference values
in these patient categories.
Introduction
Electrolyte disorders can be the consequence of acquired
or inherited renal tubular defects that cause malfunction-
ing of channels and transporters that are critically
involved in the (re)absorption or secretion of electrolytes.
These tubular disorders are rare, and knowledge about as
well as experience with validated clinical diagnostic tools
such as tubular function tests is sparse. Tubular function
tests are valuable because they can help to elucidate the
underlying defect(s) and can direct more specific diagnos-
tic tests and therapy. Reference values for tubular func-
tion tests are mainly based on studies with small sample
size in young healthy volunteers (Nozu et al. 2010; Miller
et al. 1970; Colussi et al. 2007; Walsh et al. 2007).
Patients with tubular disorders, however, are frequently
older and/or have a compromised renal function. It is
important to know whether we can use the available ref-
erence values when using these tubular function tests in
such patients.
The aim of this study was to evaluate four different
tubular function tests in our institution in young healthy
individuals, older individuals and patients with compro-
mised renal function (CRF). We performed the furosemide
test that provides information on transcellular sodium-
chloride reabsorption in the thick ascending limb of
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Henle (typically used in the diagnosis of presumed Bartter
syndrome), the thiazide test that reflects activity of
sodium-chloride reabsorption in the distal convoluted
tubule (typically used in the diagnosis of presumed
Gitelman syndrome), the furosemide- fludrocortisone (FF)
test that can be used to diagnose distal renal tubular acido-
sis and the DDAVP test which assesses urinary concentra-
tion upon stimulating the collecting ducts with synthetic
desmopressin (DDAVP) used in the diagnosis of a
renal concentration defect and/or nephrogenic diabetes
insipidus.
Materials and Methods
Study population
We performed four different tubular function tests in
three groups of volunteers: healthy individuals aged
18–50 years, healthy individuals over 50 years old and
patients with CRF. CRF was defined as an eGFR of less
than 90 mL/min/1.73 m2 based on the CKD-EPI for-
mula. For each tubular function test, we included 10
individuals per group. Exclusion criteria were pregnancy,
severe heart failure, disorders of sodium or potassium
balance, kidney disease primarily involving the kidney
tubule such as tubulo-interstitial nephritis or suggested
by an urinary alpha-1-microglobulin level of ≥40 mg/
10 mmol creatinine. After informed consent, each volun-
teer participated in one or more tubular function tests.
The tests were performed in the Radboud university
medical center by a group of trained nurses. If partici-
pating in more than one test, the tests were performed
at least 7 days apart. This study was approved by the
medical ethics committee of the Radboud university
medical center in Nijmegen, the Netherlands, and all
participants gave written informed consent.
Duplicate urine and serum samples of all tests were
stored in a freezer at 80°C.
To investigate whether there were differences between
the use of an oral fluid load or an intravenous fluid load
during the furosemide test and thiazide test, both tests
were performed in duplicate in five young healthy volun-
teers: once with an oral fluid load as described below and
once using NaCl 0.45% at 250 mL/h during the test. No
statistically significant differences between oral and intra-
venous fluid loads were noted with respect to furosemide
and thiazide test results (data not shown). We therefore
choose to perform furosemide and thiazide tests with an
oral fluid load.
The protocols of the tubular function tests are based
on previous reports in literature (Nozu et al. 2010;
Miller et al. 1970; Colussi et al. 2007; Walsh et al.
2007).
Furosemide test
In the 7 days preceding the test, subjects were not allowed
to take diuretics or non steroidal anti-inflammatory drugs
(NSAID’s). In the 3 days preceding the test, subjects were
not allowed to take angiotensin converting enzyme inhibi-
tors (ACEi) or angiotensin receptor blockers (ARB). On
the morning of the test, subjects were allowed to have a
small breakfast without coffee. During the test, participants
were allowed to eat one sandwich. They visited the clinic at
8:00 h. At that time (T = 0), body weight and blood pres-
sure were measured and a urine sample was taken. There-
after, they were instructed to drink 10 mL/kg of body
weight water in 15 min time. After 45, 90, and 120 min, a
urine sample was collected. After 150 min (T = 150), blood
and urine samples were collected and one dose of furose-
mide was given orally. If the eGFR was >60 mL/min/
1,73 m2, 40 mg of furosemide was given. If the eGFR was
between 30 and 60 ml/min/1.73 m2, 60 mg furosemide was
given, and if the eGFR was below 30 ml/min/1.73 m2,
80 mg of furosemide was given. From this moment on, the
subject was instructed to drink 250 mL of water per hour
until the end of the test. Urine was collected every 30 min
until T = 330 min and at T = 270 an additional blood
sample was collected. At the end of the test (T = 330), body
weight and blood pressure were measured again.
Thiazide test
In the 7 days preceding the test, subjects were not allowed
to take diuretics or NSAID’s. In the 3 days preceding the
test, subjects were not allowed to take ACEi or ARB. On
the morning of the test, subjects were allowed to have a
small breakfast without coffee. During the test, partici-
pants were allowed to eat one sandwich. They visited the
clinic at 8:00 h. At that time (T = 0), body weight and
blood pressure were measured and a urine sample was
taken. Thereafter, they were instructed to drink 10 mL/kg
of body weight water in 15 min time. After 45, 90, and
120 min, a urine sample was collected. After 150 min
(T = 150), blood and urine samples were collected and
50 mg of hydrochlorothiazide was given orally. From this
moment on, the subject was instructed to drink 250 mL
of water per hour until the end of the test. Urine was col-
lected every 30 min until T = 510 min and at T = 270
and T = 510, an additional blood sample was collected.
At the end of the test (T = 510), body weight and blood
pressure were measured again.
Furosemide Fludrocortisone test (FF test)
In the 7 days preceding the test, subjects were not allowed
to take diuretics, NSAID’s or sodium bicarbonate. On the
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morning of the test, the subjects were allowed to have a
small breakfast without coffee. Subjects visited the clinic
at 8:00 h in the morning. At that time, body weight and
blood pressure were measured, blood was withdrawn, a
urine sample was taken and 40 mg of furosemide and
1 mg of fludrocortisone were given orally. If the eGFR
was between 30 and 60 mL/min/1.73 m2, a gift of 60 mg
furosemide was given. If the eGFR was below 30 mL/min/
1.73 m2, a gift of 80 mg of furosemide was given. There-
after, urine samples were collected every hour during four
hours. After 120 min (T = 120) and 240 min (T = 240)
an additional blood sample was withdrawn. At the end of
the test (T = 240), body weight and blood pressure were
measured again.
DDAVP test
In the 7 days preceding the test, subjects were not allowed
to take diuretics or NSAID’s. In the 24 h preceding the
test, the subjects were not allowed to smoke cigarettes or
drink alcohol or coffee. From 22:00 h on the evening
before the test, they were not allowed to drink anymore,
and during the test they were not allowed to drink or eat.
The subjects visited the clinic at 8:00 h in the morning.
At that time (T = 0) body weight and blood pressure
were measured, blood was withdrawn, a urine sample was
taken and 4 lg of desmopressin was given subcuta-
neously. Thereafter, urine was collected every hour during
6 h. At T = 180 and T = 360 an additional blood sample
was withdrawn. At the end of the test (T = 360), body
weight and blood pressure were measured again.
Calculations and assays
Urinary chloride was measured using an ion selective
electrode for the cobas system (Roche Diagnostics). If the
urine chloride concentration was reported as <20 mmol/
L, calculations were done with 20 mmol/L. Fractional
chloride excretion (FeCl) was calculated using the formula
((urine chloride * serum creatinine)/(urine creatinine *
serum chloride)) *100. Urinary concentration of
hydrochlorothiazide was measured by liquid chromatog-
raphy-mass spectrometry (LCMS). Urine pH was mea-
sured using a pH meter (PHM220, Hach, Tiel, the
Netherlands).
Statistics
Baseline characteristics are reported as median values with
interquartile ranges. For statistical analyses, results in the
experimental groups (either the elderly or the patients
with CRF) were compared with results in the young
healthy controls. Differences were analyzed with the
Mann–Whitney U test. Differences between groups for
categorical values were analyzed by the chi square test. A
result was considered statistically significant if the P value
was <0.03 according to the Bonferroni correction.
Results
We performed 129 tubular function tests in 53 individu-
als. No serious adverse events occurred. Test results are
shown in Figures 1-4 and Tables S1-S4. Urine chloride
was below the level of detection of 20 mmol/L in 24/570
samples of the furosemide and thiazide tests.
Young healthy individuals
Clinical characteristics of young healthy individuals are
given for each separate test in the supplementary Tables
S1–S4. Overall, there were more female than male partici-
pants. Median age was 21 years (IQR 21-24). Test results
were in line with earlier reports. The median maximal
increase in FeCl (ΔFeCl) was 16.4% (range 10.3–26.3)
after furosemide and 2.9% (range 2.5–5.1) after
hydrochlorothiazide (Figs. 1 and 2, Tables S1 and S2). In
all subjects urine pH was below 5.3 in the FF test (Fig. 3,
Table S3). Median maximal urine osmolality after
DDAVP was 1002 mosmol/kg H2O (range 782–1129)
(Fig. 4, Table S4).
Figure 1. Furosemide test. Maximal increase in fractional excretion
of chloride (ΔFeCl) after administration of furosemide in young
healthy individuals (young), older healthy individuals (old), and
patients with compromised renal function (eGFR 60–89 mL/min/
1.73 m2 □, eGFR 45–60 mL/min/1.73 m2 ▼, eGFR 30–44 mL/min/
1.73 m2 ○ and eGFR 15–29 mL/min/1.73 m2 ▲).
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Older healthy individuals
Clinical characteristics per test are given in the supple-
mentary Tables S1–S4. Overall, there were more male
than female participants. Median age was 67 years (IQR
63–68). The decrease in urine pH after FF was similar to
young healthy individuals (P = 0.35). Older individuals
showed an attenuated response to furosemide, thiazide
and DDAVP compared to young healthy individuals
(P < 0.05). In five subjects ΔFeCl remained below the
lower end of the range of young healthy individuals
(10.3%) after furosemide and in six subjects ΔFeCl
remained below the lower end of the range of young
healthy individuals (2.5%) after hydrochlorothiazide
(Fig. 1 and 2, Table S1 and S2). Median maximal urine
osmolality after DDAVP was 820 mosmol/kg H2O (range
674–1044) (Figure 4). All but one of the older subjects
lowered their urine pH below 5.3 during the FF test
(Fig. 3, Table S3).
Patients with CRF
Clinical characteristics per test are given in the supple-
mentary Tables S1–S4. Overall, there were more male
than female participants with CRF. Median age was
68 years (IQR 57–72), median eGFR 49 mL/min/1.73 m2
(IQR 33–61) and median urinary alpha-1-microglobulin
Figure 2. Thiazide test. Maximal increase in fractional excretion of
chloride (ΔFeCl) after administration of hydrochlorothiazide in
young healthy individuals (young), older healthy indivduals (old),
and patients with compromised renal function (eGFR 60–89 mL/
min/1.73 m2 □, eGFR 45–60 mL/min/1.73 m2 ▼, eGFR 30–44 mL/
min/1.73 m2 ○ and eGFR 15–29 mL/min/1.73 m2 ▲).
Figure 3. Furosemide Fludrocortisone (FF) test. Urine pH after
administration of furosemide and fludrocortisone in young healthy
individuals (young), older healthy individuals (old), and patients with
compromised renal function (eGFR 60–89 mL/min/1.73 m2 □, eGFR
45–60 mL/min/1.73 m2 ▼, eGFR 30–44 mL/min/1.73 m2 ○ and
eGFR 15–29 mL/min/1.73 m2 ▲).
Figure 4. DDAVP test. Maximal urine osmolality after
administration of desmopressin in young healthy volunteers
(young), older healthy volunteers (old), and patients with
compromised renal function (eGFR 60–89 mL/min/1.73 m2 □, eGFR
45–60 mL/min/1.73 m2 ▼, eGFR 30–44 mL/min/1.73 m2 ○ and
eGFR 15–29 mL/min/1.73 m2 ▲).
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excretion 15 mg/10 mmol creatinine (IQR 7–28). The
underlying kidney disease was considered to be renovas-
cular in nine patients, secondary focal segmental glomeru-
losclerosis in three patients and primarily of urologic
origin in two patients. Eleven patients with CRF used an
ACEi or ARB and four patients with CRF were on
chronic diuretic therapy (which were stopped per the par-
ticular test protocol). Patients with CRF showed a wide
variation with respect to response to furosemide and thi-
azide (Figs. 1 and 2). Overall the increase in FeCl after
hydrochlorothiazide in CRF patients was lower compared
to healthy individuals (P < 0.01). In contrast, the increase
in FeCl after furosemide was not lower in CRF patients
compared to healthy individuals (P = 0.12). In two sub-
jects ΔFeCl remained below the lower end of the range of
young healthy individuals (10.3%) after furosemide and
in seven subjects ΔFeCl remained below the lower end of
the range of young healthy individuals (2.5%) after
hydrochlorothiazide. The peak of FeCl after
hydrochlorothiazide occurred later in patients with CRF,
although the difference was not statistically significant. In
view of the wide range in ΔFeCl in response to
hydrochlorothiazide, we determined hydrochlorothiazide
concentrations using LCMS in urine samples collected at
the time of maximal ΔFeCl. Urine hydrochlorothiazide
excretion varied between patients and was not explained
by variations in eGFR (data not shown). However, we
observed a significant correlation between hydrochloro-
thiazide excretion and chloride excretion (Fig. 5). In all
but one CRF patient, urine pH fell below 5.3 during the
FF test. Lowest urine pH did not significantly differ
between CRF patients and healthy individuals (P = 0.97).
Patients with CRF showed an attenuated response to
DDAVP compared to healthy individuals (P < 0.01), with
a median maximal urine osmolality after DDAVP of
624 mosmol/kg/H2O (range 397–866) (Fig. 4).
Discussion
Tubular function tests can be used to pin-point a tubular
defect of electrolyte transport to a specific tubular seg-
ment or function, after which other tests might detect the
underlying cause, for example, genetic testing in pre-
sumed genetic renal tubular disorders. While the latter
diagnostic technique seems to be taking over the role of
tubular function testing in some disorders, we should
realize that genetic testing is not readily available in large
parts of the world and that tubular function testing can
also be very instrumental and informative in disorders
without (known) genetic basis. In this study we tested
whether reference values for tubular function tests
obtained in young healthy individuals can be extrapolated
to older individuals and patients with compromised renal
function.
The response to FF was similar to young healthy indi-
viduals in nearly all older individuals and patients with
CRF. This is in line with earlier reports that showed that
patients with CRF are still capable of lowering their urine
pH (Wrong and Davies 1959; Tizianello et al. 1980). This
may partly be explained by the reduced ammonium gen-
eration in patients with CRF, which limits the buffer
capacity. Interestingly, one of the patients in both the
older and CKD groups did not acidify their urine within
4 h. However, this could still be due to the 4 h follow-up
being too short in these particular patients and we there-
fore cannot exclude that these patients are still be able to
(normally) acidify their urine. The responses to furose-
mide, hydrochlorothiazide and DDAVP, however, differed
between young healthy individuals, older individuals and
patients with CRF. If one would apply the often quoted
reference values for the furosemide and thiazide test to
elderly and patients with CRF, about 50% of subjects
would have an abnormal test result. Colussi et al. (2007)
previously showed that an increase in ΔFeCl in response
to hydrochlorothiazide of less than 2.3% diagnoses Gitel-
man syndrome with a sensitivity of 93% and specificity of
100%. Using this cut-off value, none of the healthy young
adults but five out of ten older individuals and six out of
ten patients with CRF, would have a false-negative test
result compatible with this diagnosis. CRF patients fur-
thermore showed a remarkable wide variation in
response. We hypothesized that this variation could be
due to differences in tubular secretion. Therefore, we
measured urine hydrochlorothiazide concentrations in all
patients with CRF and in five healthy volunteers at the
time of maximal FeCl during the thiazide test. Patients
with CRF had a lower median thiazide excretion than
Figure 5. Correlation between hydrochlorothiazide excretion and
chloride excretion in patients with compromised renal function
(closed circles) and healthy volunteers (open squares)
ª 2017 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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young healthy individuals (33 lg/min vs. 65 lg/min,
P = 0.01). There was a correlation between hydrochlorothi-
azide excretion and chloride excretion (Fig. 5, R2 = 0.48,
P < 0.01). The urine hydrochlorothiazide concentration
did not correlate with eGFR. This indicates that the often
lower and variable response to hydrochlorothiazide in
patients with CRF is possibly explained by a variable tubu-
lar secretion of hydrochlorothiazide. Hydrochlorothiazide
and furosemide are excreted from the blood into the proxi-
mal tubular lumen via organic anion transporters (OAT),
mainly OAT1. OAT1 is inhibited by uremic toxins which
could explain the reduced tubular excretion in CRF (Hsueh
et al. 2016). The individual variation within the group of
patients with CRF in OAT-mediated transport can addi-
tionally be explained by polymorphisms of OAT expres-
sion, the underlying kidney disease, co-medication and
competition with other anions (Nigam et al. 2015). An
important difference between the furosemide and thiazide
test we performed is the adjustment of furosemide dose for
eGFR. This could have led to relatively better urinary avail-
ability of furosemide compared to hydrochlorothiazide in
participants with CRF, and thereby to less difference in
response to furosemide than hydrochlorothiazide com-
pared to the healthy young adults. Additional studies are
needed to investigate whether tubular secretion of
hydrochlorothiazide and furosemide are disturbed in
elderly as well and to see if chloride excretion factored for
hydrochlorothiazide or furosemide excretion is a more
informative parameter. Another explanation for the varia-
tion in response encountered in CRF patients could be a
difference in NCC expression. NCC expression could vary
due to the underlying disease, plasma potassium and
aldosterone levels and could be affected by previous drug
use, albeit all possible confounding drugs were stopped
beforehand (Rojas-Vega and Gamba 2016).
In response to DDVAP, older individuals and patients
with CRF had a lower maximal urine osmolality than young
healthy individuals. The age-dependent decrease in maximal
urine concentrating ability is in line with the results of Tryd-
ing et al. (1988). These authors performed DDAVP tests in
212 healthy adults aged 20–80 years. Peak urine osmolality
declined with age ranging from 982  214 mOsm/kg at
20 years to 823  278 mOsm/kg at 80 years.
While our study shows that results of renal tubular func-
tion tests are dependent on age and kidney function, the
main limitation of this study is the low number of partici-
pants which precludes true definition of reference values
for older individuals and patients with compromised kid-
ney function. Besides this, it would have been informative
to obtain standard urinary concentrations of furosemide
and hydrochlorothiazide to give insight into the underlying
mechanisms explaining the differences in test results
between individual patients and groups. Another limitation
is the urinary chloride concentration that was below the
level of detection in a small amount of individuals in both
baseline samples. We performed calculations using a urine
chloride concentration of 20 mmol/L in these patients, but
this could have led to incorrect higher baseline FeCl values
and thereby lower ΔFeCl values in these individuals. How-
ever, when we excluded these individuals, the overall con-
clusion did not change. Another limitation concerns the
heterogeneity of CRF patients as these patients have differ-
ent underlying kidney diseases and (chronic) medication
use. Chronic diuretic use could have influenced the natri-
uretic response according to the braking phenomenon,
which is postdiuresis sodium avidity after diuretic use,
despite that these drugs were stopped for 7 days prior to
the test (Ellison 1999). This bias cannot fully explain the
results as only one patient with chronic thiazide use under-
went a thiazide test (and did not show a reduced response)
and only two patients with chronic furosemide use under-
went a furosemide test of which one showed a reduced
response.
In conclusion, reference values for tubular function
tests obtained in young healthy adults cannot be readily
extrapolated to older subjects or patients with compro-
mised renal function, except for the FF test. Larger studies
with measurement of urine drug concentrations would be
necessary to determine correct and clinically relevant ref-
erence values in these subject categories. For now, we
should take the results of this validation study into
account when interpreting results from patients of older
age or with compromised renal function.
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